Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum

Nature

Volumn 523, Issue 7561, 2015, Pages 477-480

  Vinayak, Sumiti ^a   Pawlowic, Mattie C ^a   Sateriale, Adam ^a   Brooks, Carrie F ^a   Studstill, Caleb J ^a   Bar Peled, Yael ^a   Cipriano, Michael J ^a   Striepen, Boris ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROMOMYCIN; AMINOGLYCOSIDE; ANTIMALARIAL AGENT; THYMIDINE KINASE; TRIMETHOPRIM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHILD MORTALITY; DIARRHEAL DISEASE; DISEASE SEVERITY; DRUG; GENETICALLY MODIFIED ORGANISM; IMMUNOASSAY; PROTOZOAN; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DNA END JOINING REPAIR; DNA FLANKING REGION; DNA MODIFICATION; FEMALE; GENE INACTIVATION; GENOME; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTIOUS DIARRHEA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TISSUE CULTURE; TRANSGENICS; TRANSIENT TRANSFECTION; ANIMAL; CELL LINE; COMPLICATION; CRISPR CAS SYSTEM; DEFICIENCY; DIARRHEA; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENE DELETION; GENETIC ENGINEERING; GENETIC TRANSFECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; INTESTINE; PARASITOLOGY; PROCEDURES; REPORTER GENE; SPOROZOITE;

ANIMALIA; CRYPTOSPORIDIUM; CRYPTOSPORIDIUM PARVUM; HUMAN IMMUNODEFICIENCY VIRUS; PROTOZOA; ROTAVIRUS;

AMINOGLYCOSIDES; ANIMALS; ANTIMALARIALS; CELL LINE; CRISPR-CAS SYSTEMS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DIARRHEA; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; FEMALE; GENE DELETION; GENE KNOCKOUT TECHNIQUES; GENES, REPORTER; GENETIC ENGINEERING; HUMANS; INTESTINES; MICE; MODELS, ANIMAL; SPOROZOITES; THYMIDINE KINASE; TRANSFECTION; TRIMETHOPRIM;

EID: 84937933550     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14651     Document Type: Article

References (41)

1. Kotloff, K. L. et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382, 209-222 (2013).
2. Mondal, D. et al. Contribution of enteric infection, altered intestinal barrier function, and maternal malnutrition to infant malnutrition in Bangladesh. Clin. Infect. Dis. 54, 185-192 (2012).
3. Checkley, W. et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect. Dis. 15, 85-94 (2015).
4. Liu, L. et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379, 2151-2161 (2012).
5. Raja, K. et al. Prevalence of cryptosporidiosis in renal transplant recipients presenting with acute diarrhea at a single center in Pakistan. J. Nephropathol. 3, 127-131 (2014).
6. Hunter, P. R.Nichols, G. Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin. Microbiol. Rev. 15, 145-154 (2002).
7. Amadi, B. et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360, 1375-1380 (2002).
8. Amadi, B. et al. Highdose prolongedtreatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect. Dis. 9, 195 (2009).
9. Striepen, B. Parasitic infections: time to tackle cryptosporidiosis. Nature 503, 189-191 (2013).
10. Upton, S. J., Tilley, M. Brillhart, D. B. Comparative development of Cryptosporidium parvum (Apicomplexa) in 11 continuous host cell lines. FEMS Microbiol. Lett. 118, 233-236 (1994).
11. Gut, J. Nelson, R. G. Cryptosporidium parvum: synchronized excystation in vitro and evaluation of sporozoite infectivity with a new lectin-based assay. J. Eukaryot. Microbiol. 46, 56S-57S (1999).
12. Hall, M. P. et al. Engineered luciferase reporter froma deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem. Biol. 7, 1848-1857 (2012).
13. Abrahamsen, M. S. et al. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 304, 441-445 (2004).
14. Theodos, C. M., Griffiths, J. K., DOnfro, J., Fairfield, A. Tzipori, S. Efficacy of nitazoxanide against Cryptosporidium parvumin cell culture and in animalmodels. Antimicrob. Agents Chemother. 42, 1959-1965 (1998).
15. Mochizuki, K. High efficiency transformation of Tetrahymena using a codonoptimized neomycin resistance gene. Gene 425, 79-83 (2008).
16. Gueiros-Filho, F. J. Beverley, S. M. On the introduction of genetically-modified Leishmania outside the laboratory. Exp. Parasitol. 78, 425-428 (1994).
17. Fox, B. A., Ristuccia, J. G., Gigley, J. P. Bzik, D. J. Efficient gene replacements in Toxoplasma gondii strains deficient for nonhomologous end-joining. Eukaryot. Cell 8, 520-529 (2009).
18. Lee, A. H., Symington, L. S. Fidock, D. A. DNA repair mechanisms and their biological roles in themalaria parasite Plasmodium falciparum. Microbiol.Mol. Biol. Rev. 78, 469-486 (2014).
19. Brooks, C. F. et al. The Toxoplasma apicoplast phosphate translocator links cytosolic and apicoplastmetabolismand is essential for parasite survival. Cell Host Microbe 7, 62-73 (2010).
20. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
21. Sidik, S. M., Hackett, C. G., Tran, F., Westwood, N. J. Lourido, S. Efficient genome engineering of Toxoplasma gondii using CRISPR/Cas9. PLoS ONE 9, e100450 (2014).
22. Griffiths, J. K., Theodos, C., Paris, M. Tzipori, S. The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum. J. Clin. Microbiol. 36, 2503-2508 (1998).
23. Fayer, R., Nerad, T., Rall, W., Lindsay, D. S. Blagburn, B. L. Studies on cryopreservation of Cryptosporidium parvum. J. Parasitol. 77, 357-361 (1991).
24. Liu, J., Bolstad, D. B., Bolstad, E. S. D., Wright, D. L. Anderson, A. C. Towards new antifolates targeting eukaryotic opportunistic infections. Eukaryot. Cell 8, 483-486 (2009).
25. Striepen,B. et al.Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc. Natl Acad. Sci. USA 101, 3154-3159 (2004).
26. Salic, A. Mitchison, T. J. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc. Natl Acad. Sci. USA 105, 2415-2420 (2008).
27. Striepen, B. in Antimicrobial Drug Resistance Vol. 1 (eds Mayers, D. L., Lerner, S. A., Ouellette, M. Sobel, J. D.) 605-621 (Springer, 2009).
28. Sheoran, A., Wiffin, A., Widmer, G., Singh, P. Tzipori, S. Infection with Cryptosporidium hominis provides incomplete protection of the host against Cryptosporidium parvum. J. Infect. Dis. 205, 1019-1023 (2012).
29. McDonald, V., Deer, R., Uni, S., Iseki, M. Bancroft, G. J. Immune responses to Cryptosporidiummuris and Cryptosporidium parvum in adult immunocompetent or immunocompromised (nude and SCID) mice. Infect. Immun. 60, 3325-3331 (1992).
30. Jiang, L., Lee, P. C., White, J. Rathod, P. K. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum. Antimicrob. Agents Chemother. 44, 1047-1050 (2000).
31. Harb, O. S.Roos, D. S. The Eukaryotic PathogenDatabases: a functional genomic resource integrating data fromhuman and veterinary parasites. MethodsMol. Biol. 1201, 1-18 (2015).
32. van Dooren, G. G., Tomova, C., Agrawal, S., Humbel, B.M. Striepen, B. Toxoplasma gondii Tic20 is essential for apicoplast protein import. Proc. Natl Acad. Sci. USA 105, 13574-13579 (2008).
33. Gubbels, M. J., Li, C. Striepen, B. High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein. Antimicrob. Agents Chemother. 47, 309-316 (2003).
34. Saeij, J. P., Boyle, J. P., Grigg, M. E., Arrizabalaga, G. Boothroyd, J. C. Bioluminescence imaging of Toxoplasma gondii infection in living mice reveals dramatic differences between strains. Infect. Immun. 73, 695-702 (2005).
35. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
36. Chakrabarti, K. et al. Structural RNAs of known and unknown function identified in malaria parasites by comparative genomics and RNA analysis. RNA 13, 1923-1939 (2007).
37. Striepen, B. Soldati, D. in Toxoplasma gondii: The Model Apicomplexan - Perspective and Methods (eds Weiss, L. M. Kim, K.) 391-415 (Elsevier, 2007).
38. Sharling, L. et al. A screening pipeline for antiparasitic agents targeting cryptosporidiuminosine monophosphate dehydrogenase. PLoS Negl. Trop. Dis. 4, e794 (2010).
39. Bessoff, K., Sateriale, A., Lee, K. K. Huston, C. D. Drug repurposing screen reveals FDA-approved inhibitors of humanHMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob. Agents Chemother. 57, 1804-1814 (2013).
40. Mary, C. et al. Multicentric evaluation of a new real-time PCR assay for quantification of Cryptosporidium spp. and identification of Cryptosporidium parvum and Cryptosporidium hominis. J. Clin. Microbiol. 51, 2556-2563 (2013).
41. Upton, S. J. in Cryptosporidium and Cryptosporidiosis (ed. Fayer, R.) 181-207 (CRC, 1997).